# Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT06544785** · PHASE2 · RECRUITING · sponsor: **PETHEMA Foundation** · enrollment: 106 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Zanubrutinib Oral Product
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT06544785
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-02
- **Primary completion:** 2032-05-31
- **Final completion:** 2032-05-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544785, "Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06544785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*